BR112022026997A2 - Vetor de vírus adeno-associado para quadro de leitura aberto dwarf - Google Patents
Vetor de vírus adeno-associado para quadro de leitura aberto dwarfInfo
- Publication number
- BR112022026997A2 BR112022026997A2 BR112022026997A BR112022026997A BR112022026997A2 BR 112022026997 A2 BR112022026997 A2 BR 112022026997A2 BR 112022026997 A BR112022026997 A BR 112022026997A BR 112022026997 A BR112022026997 A BR 112022026997A BR 112022026997 A2 BR112022026997 A2 BR 112022026997A2
- Authority
- BR
- Brazil
- Prior art keywords
- associated virus
- adeno
- dwarf
- reading frame
- open reading
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title abstract 4
- 102100034401 Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator DWORF Human genes 0.000 title abstract 3
- 101710112310 Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator DWORF Proteins 0.000 title abstract 3
- 210000002845 virion Anatomy 0.000 abstract 2
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048743P | 2020-07-07 | 2020-07-07 | |
| PCT/US2021/040428 WO2022010834A1 (en) | 2020-07-07 | 2021-07-06 | Adeno-associated virus vector for dwarf open reading frame |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026997A2 true BR112022026997A2 (pt) | 2023-03-07 |
Family
ID=79552029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026997A BR112022026997A2 (pt) | 2020-07-07 | 2021-07-06 | Vetor de vírus adeno-associado para quadro de leitura aberto dwarf |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230241249A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4179083A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534647A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230035584A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115885043A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021306697A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026997A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183844A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299638A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023000318A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022010834A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021142267A1 (en) | 2020-01-08 | 2021-07-15 | Scarpmap Llc | Methods and computing system for processing ultrasound image to determine health of subdermal tissue |
| TW202317768A (zh) | 2021-07-08 | 2023-05-01 | 美商特納亞治療股份有限公司 | 用於基因療法的優化表現卡匣 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| EP1668143B1 (en) * | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| US10570183B2 (en) * | 2016-04-19 | 2020-02-25 | The Board Of Regents Of The University Of Texas System | Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload |
| WO2018026766A1 (en) * | 2016-08-01 | 2018-02-08 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treating cardiac injury |
| CA3052705A1 (en) * | 2017-02-24 | 2018-08-30 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomixer-promoted muscle cell fusion |
| US20180326022A1 (en) * | 2017-04-21 | 2018-11-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for improving heart function and treating heart failure |
| WO2019060619A1 (en) * | 2017-09-20 | 2019-03-28 | The Regents Of The University Of California | STRATEGY OF GENE THERAPY FOR RESTORING ELECTRICAL AND CARDIAC FUNCTION AND CARDIAC STRUCTURE IN ARYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY |
| EP3870148A4 (en) * | 2018-10-25 | 2022-11-09 | Takeda Pharmaceutical Company Limited | AAV TRIPLE PLASMID SYSTEM |
| CN114450411A (zh) * | 2019-04-01 | 2022-05-06 | 特纳亚治疗股份有限公司 | 具有工程化衣壳的腺相关病毒 |
| AU2021259422A1 (en) * | 2020-04-20 | 2022-12-08 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
-
2021
- 2021-07-06 US US18/004,522 patent/US20230241249A1/en active Pending
- 2021-07-06 MX MX2023000318A patent/MX2023000318A/es unknown
- 2021-07-06 JP JP2023501075A patent/JP2023534647A/ja active Pending
- 2021-07-06 BR BR112022026997A patent/BR112022026997A2/pt not_active Application Discontinuation
- 2021-07-06 AU AU2021306697A patent/AU2021306697A1/en not_active Abandoned
- 2021-07-06 CA CA3183844A patent/CA3183844A1/en active Pending
- 2021-07-06 WO PCT/US2021/040428 patent/WO2022010834A1/en not_active Ceased
- 2021-07-06 CN CN202180048248.3A patent/CN115885043A/zh active Pending
- 2021-07-06 IL IL299638A patent/IL299638A/en unknown
- 2021-07-06 KR KR1020237001979A patent/KR20230035584A/ko not_active Withdrawn
- 2021-07-06 EP EP21838575.5A patent/EP4179083A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183844A1 (en) | 2022-01-13 |
| WO2022010834A1 (en) | 2022-01-13 |
| JP2023534647A (ja) | 2023-08-10 |
| IL299638A (en) | 2023-03-01 |
| MX2023000318A (es) | 2023-02-09 |
| KR20230035584A (ko) | 2023-03-14 |
| AU2021306697A1 (en) | 2023-02-09 |
| US20230241249A1 (en) | 2023-08-03 |
| EP4179083A4 (en) | 2024-08-28 |
| CN115885043A (zh) | 2023-03-31 |
| EP4179083A1 (en) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010275A (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este. | |
| BR112021020054A2 (pt) | Capsídeos de vírus adeno-associado (aav) e composições contendo os mesmos | |
| BR112023001336A2 (pt) | Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina) | |
| BR112022013581A2 (pt) | Processo para preparar vetores virais adenoassociados | |
| BR112023001852A2 (pt) | Terapia gênica com placofilina-2 (pkp2) usando vetor de aav | |
| BR112021018776A2 (pt) | Vetores de vírus adenoassociado recombinante | |
| MX2023001419A (es) | Vector viral adenoasociado para la expresion de glut1 y usos de este. | |
| EA202090332A1 (ru) | Улучшенная продукция капсида aav в клетках насекомых | |
| BR112021021720A2 (pt) | Composições úteis para tratamento de doença de pompe | |
| BR112012026730A2 (pt) | vetor viral adeno-associado recombinante, pluralidade de partículas virais infecciosas, células hospedeira de mamífero, kit, uso de composição, métodos para prevenir, tratar ou melhorar doença, disfunção, distúrbio, deficiência ou condição anormal em manífero de um ou mais sintomas dos mesmos, para prover quantidade terapeuticamente eficaz de peptídeo, polipeptídeo ou proteína de guanilato ciclase a mamífero biologicamente ativo em necessidade da mesma, para aumentar o nível de proteína retgc1 biologicamente em um ou mais células retinais de mamífero e para tratar ou melhorar um ou mais sintomas de distrofia retinal em mamífero | |
| BR112022011916A2 (pt) | Composições para tratar a ataxia de friedreich | |
| MX2021012311A (es) | Variantes de capsides de aav para liberacion intravitrea. | |
| MX2023000318A (es) | Vector de virus adenoasociado para marco de lectura abierto peque?o. | |
| AR126407A1 (es) | Casetes de expresión optimizada para genoterapia | |
| Dong et al. | Proteomics analysis of co-purifying cellular proteins associated with rAAV vectors | |
| PH12022550513A1 (en) | Expression vector against severe acute respiratory syndrome virus sars-cov-2 | |
| MX2022002184A (es) | Proteina vp1 modificada aislada de la capside del virus adeno-asociado de serotipo 5 (aav5), capside y vector basado en la misma. | |
| BR112022000724A2 (pt) | Proteínas de capsídeo de aav modificado para tratamento de doença artrítica | |
| EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки | |
| MX2023004420A (es) | Composiciones de virus adenoasociados recombinantes y métodos para su producción. | |
| BR112022019304A2 (pt) | Variantes de capsídeo de aav e usos das mesmas | |
| UY39426A (es) | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela) con aav-mir-sod1 | |
| BR112022003206A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| BR112022011332A2 (pt) | Vetor de vírus adeno-associado recombinante, vírus adeno-associado recombinante, e, método para tratar um indivíduo com síndrome de hunter | |
| EP4310495A3 (en) | Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |